Copy to clipboard 
RoosterBio, supplier of human mesenchymal stem/stromal cell (hMSC) working cell banks and hMSC bioprocess systems, expanded its facility in Frederick, Maryland for the second time in 2019. The addition of 5,000 square feet to its existing 15,500 footprint supports the company’s expansion efforts and provides infrastructure to meet growing international demand for its standardized hMSC bioprocess tools. The company is strengthening its cell manufacturing solution portfolio and presence in the Asia Pacific and European regions.
The new space will increase shipping capabilities for a growing international network by the end of 2019. RoosterBio announced the first expansion of its facility earlier this year which served as a catalyst for its strategic international growth initiatives. The company plans to launch an international presence in Asia during the first half of 2020.
“Our team has been working diligently this year to grow our customer base across the globe, now shipping to 26 countries and the need to expand our facility is a result of the industry validating our value proposition,” said RoosterBio’s Chief Executive Officer Margot Connor. “As our efforts have increased, we’ve increased our employee base by nearly 30% this year and we’re excited about our continued annual growth rate.” Connor added, “We’re taking RoosterBio to the next level in the international hMSC marketplace.”
RoosterBio’s products are designed to standardize hMSC manufacturing with consistent cGMP product offerings, removing time and millions of dollars from traditional mesenchymal cell therapeutic product development and clinical translation efforts.
